SCHEMBL2889221

SCHEMBL2889221

CC(C)(C)Oc1ccc2c(n1)OCCN(Cc1ccccc1)C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER2 P43116 6/20 0.40
GRM5 P41594 1/20 0.40
CYP1A2 P05177 2/20 0.39
TMEM97 Q5BJF2 4/20 0.38
SIGMAR1 Q99720 4/20 0.38
ADRA2A P08913 2/20 0.38
ADRA2B P18089 2/20 0.38
DRD4 P21917 2/20 0.38
HTR2B P41595 2/20 0.38
HRH1 P35367 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
ADRA2C P18825 1/20 0.38
ALOX15 P16050 1/20 0.37
CYP2C19 P33261 1/20 0.37
MC4R P32245 1/20 0.37
CHRM2 P08172 1/20 0.36
HTR1A P08908 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2889094 0.84 KDM4E (0.44) PTGER2GRM5CYP1A2TMEM97SIGMAR1
SCHEMBL2111899 0.81 CYP1A2 (0.44) PTGER2CYP1A2TMEM97SIGMAR1ADRA2A
SCHEMBL2883235 0.81 PTGER2 (0.38) PTGER2GRM5CYP1A2TMEM97SIGMAR1
SCHEMBL2907874 0.80 KMT2A (0.54) TMEM97SIGMAR1DRD4HTR2BMEN1
SCHEMBL2888948 0.80 PTGER2 (0.42) PTGER2GRM5CYP1A2TMEM97SIGMAR1
SCHEMBL2891460 0.80 OPRM1 (0.42) PTGER2CYP1A2SIGMAR1DRD4
SCHEMBL2110977 0.79 CYP1A2 (0.45) PTGER2CYP1A2TMEM97SIGMAR1ADRA2A
SCHEMBL2891609 0.79 CYP1A2 (0.37) PTGER2GRM5CYP1A2TMEM97SIGMAR1
SCHEMBL13970695 0.78 MEN1 (0.44) PTGER2CYP1A2TMEM97SIGMAR1ADRA2A
SCHEMBL2887318 0.78 KDM4E (0.44) PTGER2TMEM97SIGMAR1ADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2213675-B1 PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2013-08-14 EP disclosed
US-8329687-B2 Pyridooxazepine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-20100286120-A1 PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-11 US disclosed
EP-2213675-A1 PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286120-A1 PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF HTR2C, HTR2A, TPH2 PTGER2 30/4885GRM5 117/4885CYP1A2 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.